Adeberg S, Bostel T, König L, Welzel T, Debus J, Combs SE (2014) A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival? Radiat Oncol 9:95. https://doi.org/10.1186/1748-717X-9-95. Published 2014 Apr 23

Article  PubMed  PubMed Central  Google Scholar 

Batash R, Asna N, Schaffer P, Francis N, Schaffer M (2017) Glioblastoma multiforme, diagnosis and treatment; recent literature review. Curr Med Chem. 24(27):3002–3009. https://doi.org/10.2174/0929867324666170516123206

Article  CAS  PubMed  Google Scholar 

Burton EC, Lamborn KR, Forsyth P et al (2002) Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res. 8(1):180–187

CAS  PubMed  Google Scholar 

Cai J, Chen Q, Cui Y et al (2018) Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples. Oncoimmunology 7(5):e1426516. https://doi.org/10.1080/2162402X.2018.1426516. Published 2018 Feb 13

Article  PubMed  PubMed Central  Google Scholar 

Cheung-Lee WL, Link AJ (2019) Genome mining for lasso peptides: past, present, and future. J Ind Microbiol Biotechnol. 46(9–10):1371–1379. https://doi.org/10.1007/s10295-019-02197-z

Article  CAS  PubMed  Google Scholar 

Das P, Puri T, Jha P et al (2011) A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci. 18(1):66–70. https://doi.org/10.1016/j.jocn.2010.04.050

Article  CAS  PubMed  Google Scholar 

Ding W, Zhou X, Jiang G et al (2022) Identification of prognostic biomarkers of glioblastoma based on multidatabase integration and its correlation with immune-infiltration cells. J Oncol 2022:3909030. https://doi.org/10.1155/2022/3909030. Published 2022 May 31

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fazi B, Proserpio C, Galardi S et al (2019) The expression of the chemokine CXCL14 correlates with several aggressive aspects of glioblastoma and promotes key properties of glioblastoma cells. Int J Mol Sci 20(10):2496. https://doi.org/10.3390/ijms20102496. Published 2019 May 21

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gately L, Collins A, Murphy M, Dowling A (2016) Age alone is not a predictor for survival in glioblastoma. J Neurooncol. 129(3):479–485. https://doi.org/10.1007/s11060-016-2194-x

Article  CAS  PubMed  Google Scholar 

Gately L, McLachlan SA, Philip J, Rathi V, Dowling A (2019) Molecular profile of long-term survivors of glioblastoma: a scoping review of the literature. J Clin Neurosci. 68:1–8. https://doi.org/10.1016/j.jocn.2019.08.017

Article  CAS  PubMed  Google Scholar 

Han J, Puri RK (2018) Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme. J Neurooncol. 136(3):463–474. https://doi.org/10.1007/s11060-017-2680-9

Article  CAS  PubMed  Google Scholar 

Hartmann C, Hentschel B, Simon M et al (2013) Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res. 19(18):5146–5157. https://doi.org/10.1158/1078-0432.CCR-13-0017

Article  CAS  PubMed  Google Scholar 

Hertler C, Felsberg J, Gramatzki D et al (2023) Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419). Eur J Cancer. 189:112913. https://doi.org/10.1016/j.ejca.2023.05.002

Article  PubMed  Google Scholar 

Homma T, Fukushima T, Vaccarella S et al (2006) Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol. 65(9):846–854. https://doi.org/10.1097/01.jnen.0000235118.75182.94

Article  CAS  PubMed  Google Scholar 

Huang S, Cai N, Pacheco PP, Narrandes S, Wang Y, Xu W (2018) Applications of support vector machine (SVM) learning in cancer genomics. Cancer Genomics Proteomics. 15(1):41–51. https://doi.org/10.21873/cgp.20063

Article  CAS  PubMed  Google Scholar 

Jahani-Asl A, Yin H, Soleimani VD et al (2016) Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. Nat Neurosci. 19(6):798–806. https://doi.org/10.1038/nn.4295

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang K, Xie F, Wu Y et al (2021) Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma. Int Immunopharmacol. 96:107610. https://doi.org/10.1016/j.intimp.2021.107610

Article  CAS  PubMed  Google Scholar 

Krex D, Klink B, Hartmann C et al (2007) Long-term survival with glioblastoma multiforme. Brain. 130(Pt 10):2596–2606. https://doi.org/10.1093/brain/awm204

Article  PubMed  Google Scholar 

Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD (2012) The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 28(6):882–883. https://doi.org/10.1093/bioinformatics/bts034

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P (2015) The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1(6):417–425. https://doi.org/10.1016/j.cels.2015.12.004

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu J, Cowperthwaite MC, Burnett MG, Shpak M (2016) Molecular predictors of long-term survival in glioblastoma multiforme patients. PLoS One 11(4):e0154313. https://doi.org/10.1371/journal.pone.0154313. Published 2016 Apr 28

Article  CAS  PubMed  PubMed Central  Google Scholar 

Madhugiri VS, Moiyadi AV, Shetty P et al (2021) Analysis of factors associated with long-term survival in patients with glioblastoma. World Neurosurg. 149:e758–e765. https://doi.org/10.1016/j.wneu.2021.01.103

Article  PubMed  Google Scholar 

Michaelsen SR, Urup T, Olsen LR, Broholm H, Lassen U, Poulsen HS (2018) Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival. J Neurooncol. 137(3):533–542. https://doi.org/10.1007/s11060-017-2739-7

Article  CAS  PubMed  Google Scholar 

Mondal B, Patil V, Shwetha SD et al (2017) Integrative functional genomic analysis identifies epigenetically regulated fibromodulin as an essential gene for glioma cell migration. Oncogene. 36(1):71–83. https://doi.org/10.1038/onc.2016.176

Article  CAS  PubMed  Google Scholar 

Moreno DA, da Silva LS, Gomes I et al (2022) Cancer immune profiling unveils biomarkers, immunological pathways, and cell type score associated with glioblastoma patients’ survival. Ther Adv Med Oncol 14:17588359221127678. https://doi.org/10.1177/17588359221127678. Published 2022 Dec 21

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noronha C, Ribeiro AS, Taipa R et al (2022) PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma. J Neurooncol. 156(3):453–464. https://doi.org/10.1007/s11060-021-03907-3

Article  CAS  PubMed